Following Axol Bioscience and Censo Biotechnologies recent merger to form Axol Biosciences, our CSO Ashley Barnes was
invited to speak at the Neuroimmunology Drug Development Summit
alongside other experts from academia and industry on the advances being
made in this burgeoning field.
Axol Bioscience sponsored Austrian Neuroscience Association (ANA) Student, Michael Stefan Unger to attend the 10th Forum for Neuroscience Societies (FENS), which took place in Copenhagen, Denmark. Michael is a PhD student at the Institute of Molecular Regenerative Medicine, Paracelsus Medical University in Salzburg, Austria. His PhD research focuses on cellular plasticity associated with amyloid-plaques and the potential role of neurogenic cells in modulating plaque pathology in Alzheimer's disease. Michael writes about his research and shares his experience of the conference.
Our understanding of the central nervous system (CNS) has grown significantly in recent years. The advent of new technologies and products have enabled us to explore not only the molecular mechanisms involved in learning, development, memory formation, electrical conductivity and synaptic function but also the onset and deterioration of these systems in neurological disorders such as epilepsy, amyotrophic lateral sclerosis (ALS), Alzheimer’s, Huntington’s and Parkinson’s diseases as well as psychiatric conditions.